Fig. 6: TRAIL but not ABT-737 enhances sorafenib-mediated cell death in BIM-deficient HLE cells. | Cell Death & Disease

Fig. 6: TRAIL but not ABT-737 enhances sorafenib-mediated cell death in BIM-deficient HLE cells.

From: BH3-only protein expression determines hepatocellular carcinoma response to sorafenib-based treatment

Fig. 6

A Western blot analysis of the expression of pro-apoptotic (NOXA, PUMA, BIM, and BAX) and anti-apoptotic Bcl-2 molecules (MCL-1, BCL-XL) in HLE cells revealed a lack of BIM expression. B Viability of HLE cells treated for 8 h with sorafenib (7.5 µg/ml) or ABT-737 (5 µM) alone or in combination. Compared to sorafenib alone, HLE cell death was not enhanced by the combination with ABT-737. C In contrast, cell death could be strongly enhanced in HLE cells by the combination of sorafenib with TRAIL (50 ng/ml). Results of five (B, C) independent experiments are shown. Western blot analysis was performed on the same membrane as shown in Fig. 2. Significances indicated above the bars refer to control. *p < 0.05; **p < 0.01; n.s. non-significant.

Back to article page